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Abstract
Background: Reported rates of depression in 
schizophrenia vary considerably. 
Objective: To measure the prevalence of depression in 
a first episode sample of people with schizophrenia. 
Methods: All referrals with a first episode of 
schizophrenia diagnosed using SCID interviews were 
assessed pre-discharge and again six months later. 
We used the Calgary Depression Scale for Schizophre-
nia (CDSS) and Positive and Negative Syndrome Scale 
(PANSS) to assess the severity of symptoms.  
Results: Pre-discharge, 10.4% of the sample met 
CDSS criteria for depression. According to the PANSS 
depression (PANSS –D) subscale, 3% of patients were 
depressed, with a mean score of 7.48 (SD = 2.97). Only 3% 
of patients pre-discharge were found to be depressed on 
both the CDSS and the PANSS-D. Six months later 6.5% 
were depressed according to the CDSS. However none 
reached depression criteria according to the PANSS-D. 
The CDSS correlated with PANSS-D both pre-discharge 
and at follow-up. Feelings of depression and self-depre-
cation were the most common symptoms at baseline and 
follow-up.  The CDSS was unrelated to negative symp-
toms at both stages. A lifetime history of alcohol abuse 
increased the risk for depression.
Conclusion: Rates of depression in this sample were 
low. The CDSS appears to discriminate between depres-
sion and negative symptoms. Like the general population, 
alcohol misuse is a risk factor for depression in first 
episode schizophrenia.   
Key words: First episode psychosis; Schizophrenia; 
Depression; Calgary depression scale.  
Introduction
Depression among people with schizophrenia is associ-
ated with poorer quality of life, readmission and increased 
mortality through suicide.1 Estimates of the prevalence of 
depression in schizophrenia vary widely, from 7 to 75%.2 
One possible explanation for the wide variance in estimates 
may be the instrument used to measure depression. The 
Beck Depression Inventory (BDI), the Hamilton Rating Scale 
for Depression (HAM-D), and the depression subscale of the 
PANSS (PANSS-D)1 have all been used but, they may have 
difficulty in distinguishing between depressive symptoms, 
negative symptoms and side-effects from medications.3 The 
PANSS – D has been found to have a significant association 
with negative symptoms in a previous study of a stable group 
of schizophrenic patients.1 
Another possible reason for the wide variance in 
prevalence estimates may be that studies have examined 
patients at different phases of illness. Yet, depression can 
occur in the prodromal phase, acute or the post-psychotic/
stable phase and the rates, reasons and the nature of depres-
sion may vary across phases. One way to circumvent this 
methodological problem is to examine patients at the same 
phase of illness. 
Addington and colleagues formulated the Calgary Depres-
sion Scale for Schizophrenia (CDSS) specifically to measure 
distinctive depressive symptoms in schizophrenia.4 The scale 
was developed in three stages and was found to have 
construct validity, good inter-rater reliability and divergent 
validity from negative symptoms or side-effects of medication 
such as akathisia, hypokinesia and sedation.4-8 It has been 
translated into many other languages including Danish, Greek 
and French.9-11 However, despite the scale of the problem 
there are no published estimates of the prevalence of depres-
sion among people in Ireland with first episode schizophrenia. 
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We sought to determine the prevalence of depression in a 
first episode sample and its clinical correlates. Additionally, 
we examined the relationship between the CDSS and the 
PANSS. The scale has been found to have significant asso-
ciation with negative symptoms in a previous study of a stable 
group of schizophrenic patients while the CDSS had no 
such association.1 However, in a study of acutely psychotic 
patients, the CDSS scores were correlated with the PANSS 
positive subscale scores (PANSS – P).12 Our study aims 
to investigate the relationship between the CDSS and the 
PANSS in a group of first-episode schizophrenia patients to 
establish if these findings can be replicated. 
Methods 
Population
The original sample consisted of all 165 people presenting 
with first episode psychosis between 1995 and 1999  who 
resided within the geographically defined catchment area 
with a population of 165,000 at the time of the study. They 
presented either to the Cluain Mhuire Family Centre, which 
provides the public psychiatric service to the catchment area, 
or to St John of God Hospital, a private facility which provides 
care to persons from the catchment area and elsewhere. 
First-episode psychosis was defined as first lifetime pres-
entation to any psychiatric service with a psychotic episode, 
including mania, among all adolescents (12 years of age or 
over) and adults (no upper age limit). If neuroleptic medication 
had been prescribed before presentation, for example by a 
family practitioner, patients were incepted provided they had 
not been receiving medication for more than 30 days before 
referral to the service. Following approval by the Provincial 
Research Ethics Committee of the Hospitaller Order of St 
John of God all those approached gave verbal consent to 
their participation in the study. 
  
Assessments
We assessed each person with a comprehensive range 
of standardised clinical measures pre-discharge and at 
six months follow-up and these are described in detail 
elsewhere.13
Briefly, all patients were assessed using structured clinical 
interviews for diagnoses, positive and negative symptoms and 
quality of life as well as neurological functioning. At presenta-
tion, depressive symptoms were assessed with the CDSS, 
which is a nine-item observer rating scale, originally formu-
lated by factor analysis from the Present State Examination 
and the Hamilton Depression Rating Scale.4 Each item on 
the scale has a possible score of 0-3 (absent, mild, moderate, 
severe), giving a possible range of 0-27. 
The scale has been assessed for reliability and found to 
have a 0.895 intra-class correlation with 86% agreement on 
specific items after 5-10 practice interviews, and is useful 
both in clinical and research settings.5 It has high discriminant 
ability and as mentioned earlier, has been found to have no 
significant association with the PANSS – negative subscale 
(PANSS – N) (r = 0.228, ns).8 The CDSS assesses the previ-
ous two weeks unless otherwise stipulated. 
A score of 6 or 7 or more has 77% or 82% specificity 
respectively for major depression, rising to 100% for a score 
of 13 or more. We, like previous studies used a score of 
greater than 6 on the CDSS as constituting depression.6,7  
We assessed positive, negative and depressive symptoms 
using the Positive and Negative Syndrome Scale (PANSS).14 
The PANSS has three subscales which assess positive, 
negative and depressive symptoms. Each subscale grades 
symptoms from absent (score = 1) to extreme (score = 7). 
The PANSS – D has a total score of 28, the PANSS-N a total 
of 49, as does the PANSS-P. Other studies have taken remis-
sion of symptoms as being classified by no score greater 
than 3 over the previous month on any PANSS item.15,16 We 
propose using a cut-off score of >16 (corresponding to an 
average score of >4 on each item) to define depression as 
measured by the PANSS-D. 
When the patients were clinically stable, a DSM-IV 
diagnosis was ascertained using the up-dated version of 
the Structured Clinical Interview for DSM-III-R – Patient 
Version.17 
Inter-rater Reliabilities
We assessed the inter-rater reliability for the PANSS with 
the consecutive examination of 10 patients with chronic 
schizophrenia. Inter-class correlation co-efficients (ICCs) 
Characteristic CDSS performed CDSS not performed
Gender  70.1% male 71.4% male
Mean/median age 25/23 yrs 25.15/23 yrs
Inpatient status 95.5% 87.6%
Voluntary admission  78.8% 79.3%
Previous admission 6.5% 2.9%
Family history of schizophrenia 10.7% 18.5%
Married once 3.0% 3.1%
Living alone 3.2% 12.9%
Higher professional 20.0% 31.8%
Lower professional 42.0% 18.2%
Other occupation 10.0% 28.8%
Skilled  10.0% 4.5%
Semi-skilled 2.0% 6.1%
Manual  14.0% 10.6%
Paranoid schizophrenia 43.1% 38.3%
Catatonic schizophrenia .0% 3.3%
Disorganized schizophrenia 11.8% 6.7%
Undifferentiated schizophrenia 25.5% 31.7%
Residual schizophrenia 2.0% 3.3%
Schizophrenia subtype n/a 17.6% 16.7%
Lifetime history of alcohol abuse 19.4% 20.0%
Lifetime history of drug abuse/ 
dependence 30.6% 35.6%
Table 1: Characteristics of those assessed and not assessed by the 
CDSS
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were 0.73 for the PANSS-N and in excess of 0.84 for the 
remaining subscales and the total score.  
Statistical analyses
We used Chi-square tests and independent Student’s 
t-tests to look for any significant distinguishing factors 
between those who were and those who were not assessed 
with the CDSS. Pearson product moment correlations were 
used to evaluate the relationship between negative and 
depressive symptoms – as measured by both the CDSS 
and PANSS-D - in first episode schizophrenia, and again at 
six month follow-up. We employed logistic regression analy-
sis to establish whether there was any association between 
depression on the CDSS and possible risk factors using 
the Statistical Package for the Social Sciences, Version 12 
(SPSS Inc., Chicago, IL, USA).
 
Results
The original first episode group included 165 people who 
received a diagnosis of psychosis. Valid data for PANSS 
were available for 162 cases. The mean PANSS-P score 
was 17 (SD 7.3), mean PANSS-N score was 22 (SD 6.6) 
and PANSS-D score was 2.5 (SD 1.5). The CDSS was 
introduced in the third year of the study and 67 of the entire 
sample were assessed with the CDSS.  There were no statis-
tically significant differences between those who were, and 
those who were not assessed with the CDSS in terms of 
age, gender, admission status, lifetime history of drug/alcohol 
abuse and duration of prodrome at baseline (see Table 1). 
The 67 patients assessed with the CDSS included 47 men 
and 20 women who had a mean age of 25 years (SD 9.78). 
They had a mean of 13 years in education (SD 2.6). Thirty-
one of these patients were followed up with the CDSS at six 
months (46.3% follow-up). 
Pre-discharge, the mean CDSS score of the sample was 
2.16 (SD 3.07) and 10.4% met criteria for depression. 
The most prominent CDSS items at baseline were feelings 
of depression, followed by thoughts of self-depreciation. 
According to the PANSS-D, 3% of patients were depressed, 
with a mean score of 7.48 (SD 2.97). Only 3% of patients 
met criteria for depression on both the CDSS and the 
PANSS-D. 
At six month follow-up, 6.5% of patients were depressed 
on the CDSS, and the mean overall score for the sample was 
1.45 (SD = 2.82). Self-depreciation was the highest scoring 
item, with feelings of depression being the next most common 
symptom. Early morning wakening was a significant complaint 
at baseline, but was completely absent at follow-up. None of 
the patients were depressed at follow-up according to the 
PANNS-D, where the mean score was 6.53 (SD = 3.39). Of 
the seven patients found to be depressed on the CDSS at 
baseline, only two were followed up with another CDSS at 
six months, and neither of these was found to be depressed. 
Of the 6.5% of patients who met criteria for depression at 
follow-up on the CDSS, none had met the criteria for depres-
sion at baseline. 
CDSS and PANSS-D
Pre-discharge, CDSS scores were positively correlated 
with those of the PANSS-D (r = 0.744, p < 0.00), but not with 
the PANSS-N (r = 0.005, ns). There was no positive relation-
ship between the overall CDSS score and overall PANSS –P 
(r = 0.17, ns). We found further positive correlations between 
total CDSS score and PANSS items G2 (anxiety) (r = 0.38, 
p = 0.002); G3 (guilt) (r = 0.67, p = 0.00); G4 (tension) (r = 
0.35, p = 0.004); G14 (poor impulse control) (r = 0.36, p = 
.003); G16 (active social avoidance) (r = 0.36, p = 0.003) 
and finally with the total general psychopathology score (r = 
0.49, p = 0.00). This final item is thought to accurately reflect 
disease severity. We found CDSS did correlate with PANSS 
N2 (emotional withdrawal) (r = 0.29, p = 0.02), but no other 
negative subscale items.
At six month follow-up, the relationship between the CDSS 
and PANSS-D was still statistically significant (r = 0.0.888, 
p = 0.000) and there was no significant association between 
the CDSS and PANSS-N (r = -0.06, p = 0.75) or the PANSS 
– P (r = 0.081, p = 0.67). 
There were no significant relationships between the PANSS 
–D and PANSS – N (r = -.052, p = 0.686) pre-discharge, 
however there was a significant relationship between PANSS 
–D and P (r =- .337, p = .007). However at six months higher 
PANSS – D scores were associated with higher PANSS – P 
scores (r = .37, p = .001). 
Factors known to relate to depression in psychosis such as 
gender, age, treatment status, martial status, living situation, 
education and alcohol misuse were subjected to a binary 
logistic regression analysis. We found that lifetime history of 
alcohol abuse was the only significant risk factor for the pres-
ence of depression at baseline. 
 
Discussion
The prevalence of depression in this Irish population with 
first episode schizophrenia was 10.4% according to the 
CDSS. This is a lower rate than the only directly compara-
ble study examining patients in the same phase of illness 
with the same instrument and same criteria; Addington and 
colleagues found 21% of a first episode cohort in Canada 
to be depressed.7 While the difference might be accounted 
for by random variation, it is noteworthy that this Irish sample 
had higher positive symptoms and higher negative symptom 
scores than that of Addington and colleagues.7 
This may indicate either a greater severity of illness or 
perhaps indicate that the assessments were carried out in 
the acute phase of psychosis. Although we know that the 
Irish sample was assessed within thirty days, the Canadian 
study did not specify the timing of assessment. It may be that 
even when restricting samples to first episode cohorts the 
timing of assessment of depressive symptoms within that first 
episode may influence CDSS scores.18 
However, timing alone is unlikely to account for the dispar-
ity in rates since the rates of depression among the Canadian 
cohort (17%) at six months were still more than double this 
Irish sample (6.5%).7 Another possible explanation is that we 
restricted our analyses to cases of schizophrenia and schizo-
phreniform disorder but Addington and colleagues included 
those with schizoaffective disorder and delusional disorder. 
Despite these differences the numbers of such cases are 
unlikely to account for the disparity in rates. 
PANSS-D rates were 3% and 0% at inception and six 
months respectively. Pre-discharge there was only 3% agree-
ment between the PANSS-D and the CDSS. At six month 
follow up there was even less agreement. PANSS-D showed 
no significant association with the PANSS-N at inception or 
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at six month follow-up, unlike Collins and colleagues who 
found PANSS-D and PANSS-N to have a significant relation-
ship, albeit in a group of stable schizophrenic patients.1
Although the final number of people for whom we had all 
consecutive assessments was only 31 cases, these data 
confirm that choice of assessment instrument affects the 
rates of depression identified in the same group of patients at 
the same phase of illness. There is an emerging consensus 
favouring the CDSS because it distinguishes true depres-
sive symptoms from negative symptoms and medication 
side-effects.1,6 The present study extends these findings by 
indicating that the CDSS can distinguish depression from 
negative symptoms in first episode schizophrenia in the acute 
phase even in the presence of relatively high levels of positive 
and negative symptoms.  
Risk factors
We found no relationship between gender, age, martial 
status or living situation and depression among people with 
first episode schizophrenia. Educational attainment also had 
no relationship with depression. However, lifetime alcohol 
abuse was associated with the risk of depression at first 
presentation. Substance misuse, including alcohol misuse 
has a detrimental impact on recovery from psychosis.19 
However, there is a wealth of literature confirming an asso-
ciation between alcohol misuse and later depression in the 
general population.20 Therefore, alcohol misuse is likely to be 
a non-specific risk factor for depression in schizophrenia as it 
is in many other conditions.   
Conclusion 
As the CDSS has become widely used, translated into 
many languages and has a high degree of specificity, it 
seems to have earned its place as the assessment of choice 
for evaluating depression in schizophrenia. This first report in 
an Irish first episode population and one of a handful of first 
episode studies internationally, indicates a rate of depression 
of about 10% which is lower than that reported by the group 
who developed the scale, albeit similar to their rate reported 
in a group with established schizophrenia.4 As depression, 
schizophrenia and alcohol misuse are all associated with 
increased risk of suicide the confluence of such risk factors 
in the one individual may merit specific interventions.8 
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